Signition LP’s Acadia Pharmaceuticals ACAD Stock Holding History

Signition LP’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,823	Closed	-$282K	–	73
2019 Q3	$282K	Buy	+7,823	New	+$237K	1.13%	35

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Signition LP's ACAD Position: Q4 2019 in Review

Signition LP sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 7,823 shares — an estimated $282K sold.

Signition LP first reported a position in ACAD in Q3 2019 and held it in 1 quarter. The position peaked at $282K in Q3 2019. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

Signition LP reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Signition LP sold 7,823 Acadia Pharmaceuticals shares in Q4 2019, an estimated $282K.
Signition LP first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Signition LP's Acadia Pharmaceuticals position peaked at $282K in Q3 2019.
273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Signition LP's 13F filing for Q4 2019, filed 3 Feb 2020.